A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

Skin Cancer

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Melanoma Res.

Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM

doi: 10.1097/CMR.

Skin CancerLymphoma

Cystic metastatic lymph nodes in malignant melanoma: a case report

Clin Imaging.

Mema E, Cho E, Ha R, Taback B

doi: 10.1016/

Skin Cancer

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Eur J Cancer.

Heppt MV, Heinzerling L, Kähler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, Meier F, Terheyden P, Schell B, Herbst R, Göppner D, Kiecker F, Rafei-Shamsabadi D, Haferkamp S, Huber MA, Utikal J, Ziemer M, Bumeder I, Pfeiffer C, Schäd SG, Schmid-Tannwald C, Tietze JK, Eigentler TK, Berking C

doi: 10.1016/j.ejca.2017.05.038.

Skin Cancer

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

Oncotarget.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A

doi: 10.18632/oncotarget.18213.

COMMENTED

Skin CancerMultiple Myeloma (MM)

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

Hematol Oncol.

Mey UJ, Renner C, von Moos R

doi: 10.1002/hon.2353.

Gynecologic Cancer

Metastatic melanoma of the uterine cervix diagnosed on cervical Pap smear: Case report and literature review

Diagn Cytopathol.

Shachner TR, Van Meter SE

doi: 10.1002/dc.24058.

Skin Cancer

Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report

J Med Case Rep.

El-Tani Z, Duc C, Gluecker T, Cottier O

doi: 10.1186/s13256-016-1117-y

Central Nervous System Tumors

Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib

Pediatr Blood Cancer.

van Tilburg CM, Selt F, Sahm F, Bächli H, Pfister SM, Witt O, Milde T

doi: 10.1002/pbc.26893.

RECOMMENDED

Skin Cancer

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma

J Immunother.

Dimitriou F, Matter AV, Mangana J, Urosevic-Maiwald M, Micaletto S, Braun RP, French LE, Dummer R

doi: 10.1097/CJI.

Related content

Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma

Cystic metastatic lymph nodes in malignant melanoma: a case report

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

Metastatic melanoma of the uterine cervix diagnosed on cervical Pap smear: Case report and literature review

Intramammary metastatic melanoma of unknown primary origin in a 58-year old patient: a case report

Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib

Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma